Welcome to NewYorkLifeScience.com
NewYorkLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About New York's BioHistory
Why is there a biotechnology industry in New York? Will the industry continue
to grow in New York? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through New York BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of New York.
More NY BioHistory...
|
|
|
Local News...
Free News Release Posting & Archiving Service
- Applera Board of Directors approves proposed separation of its Celera business Applera Corporation announced that its board of directors has formally approved the proposed separation of the Celera Group from Applera's remaining businesses.
Celera May 09, 2008
- Progenics Pharmaceuticals reports first quarter 2008 results Progenics Pharmaceuticals announced its results of operations for the quarter ended March 31, 2008. Revenues for the quarter totaled $14.8 million compared to revenues of $17.6 million for the same period in 2007.
Progenics Pharmaceuticals, Inc. May 09, 2008
- Redpoint Bio reports first quarter 2008 results Redpoint Bio announced financial and operational results for the first quarter ended March 31, 2008. For the quarter ended March 31, 2008, Redpoint recorded revenue of $0.9 million, which includes the Company's research and development collaboration with Givaudan.
Redpoint Bio Corporation May 09, 2008
- Keryx Biopharmaceuticals announces first quarter 2008 financial results Keryx Biopharmaceuticals announced its results for the first quarter ended March 31, 2008. The net loss for the first quarter ended March 31, 2008 was $34,536,000, or $0.79 per share, compared to a net loss of $21,813,000, or $0.50 per share, for the first quarter in 2007.
Keryx Biopharmaceuticals, Inc. May 09, 2008
- Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
Bayer May 08, 2008
More... | Submit News Release | National News
|
New Job Postings...
Free Job Posting Trial Offer
More... |
Job Advertising...
| About Job Postings...
|
Upcoming Events...
Free Event Posting Service
More... |
Submit Event |
Event Advertising...
|
Deutsch |
Español |
Français |
Norsk |
Russian
|